Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> MutationBella Kaufman, Susan M. Domchek, Michael Friedländer et al.|Journal of Clinical Oncology|2014Cited by 1.7k
Administration of continuous/intermittent olaparib in ovarian cancer patients with a germline BRCA1/2 mutation to determine an optimal dosing schedule for the tablet formulationJoaquı́n Mateo, L Rhoda Molife, Michael Friedländer et al.|Unknown|2013Cited by 19